Instrumento Inactivo

Otros idiomas Opiant Pharmaceuticals, Inc.

Acciones

OPNT

US6837501039

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Indivior completes acquisition of Opiant Pharmaceuticals	02/03/23
Indivior Wraps Up Deal to Buy Opiant Pharmaceuticals	02/03/23
OPIANT PHARMACEUTICALS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	02/03/23
Opiant Pharmaceuticals, Inc.(NasdaqCM:OPNT) dropped from NASDAQ Composite Index	02/03/23
Opiant Pharmaceuticals, Inc.(NasdaqCM:OPNT) dropped from S&P TMI Index	02/03/23
Indivior PLC completed the acquisition of Opiant Pharmaceuticals, Inc. from a group of shareholders.	02/03/23
OPIANT PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	01/03/23
OPIANT PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)	27/02/23
Indivior Wins US Regulatory Nod To Acquire Opiant Pharmaceuticals	08/02/23
OPIANT PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	07/02/23
Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC	07/02/23
Jerome revient en deuxième semaine	07/02/23
En Direct des Marchés : BNP Paribas, TotalEnergies, L'Oréal, Scor, Casino, CVS, Bayer, Siemens, BP...	07/02/23
Indivior announces expiry of waiting period for Opiant purchase	06/02/23
Opiant Pharmaceuticals Says Waiting Period Expires for Proposed Takeover by Indivior Expires	06/02/23
Indivior Nears Acquisition of Opiant Pharmaceuticals	06/02/23
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC	06/02/23
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC	06/02/23
Warren tells FTC she is "particularly concerned" about Amgen and Indivior deals	26/01/23
Opiant Pharmaceuticals Granted FDA Priority Review for Opioid Overdose Therapy	20/01/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Opiant Pharmaceuticals, Inc.

Acciones

OPNT

US6837501039

Otros idiomas

Filtros